Gene
NRAS
NRAS is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (4), Assay-provider ledger (102), Actionable biomarkers (17), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NRAS. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 dated before 1990 and 39 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 36 of 8,738 | 0.41% | not measured | |
| 2025 | 35 of 8,875 | 0.39% | not measured | |
| 2024 | 33 of 8,597 | 0.38% | not measured | |
| 2023 | 30 of 8,275 | 0.36% | 90 of 11,460 | 0.79% |
| 2022 | 25 of 8,285 | 0.30% | 77 of 13,598 | 0.57% |
| 2021 | 26 of 8,692 | 0.30% | 127 of 15,045 | 0.84% |
| 2020 | 27 of 7,640 | 0.35% | 92 of 14,459 | 0.64% |
| 2019 | 21 of 7,300 | 0.29% | 100 of 12,159 | 0.82% |
| 2018 | 23 of 6,927 | 0.33% | 89 of 11,854 | 0.75% |
| 2017 | 25 of 6,558 | 0.38% | 73 of 11,595 | 0.63% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (4)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| MI Cancer Seek (MCS) | NRAS | Caris Life Sciences | Colorectal Cancer | 2024-11-05 |
| CRCDx RAS Mutation Detection Assay Kit | NRAS | EntroGen, Inc. | Colorectal Cancer (CRC) | 2023-09-29 |
| xT CDx | NRAS | Tempus Labs, Inc. | Colorectal Cancer (CRC) | 2023-04-28 |
| FoundationOne CDx | NRAS | Foundation Medicine, Inc. | Colorectal Cancer | 2017-11-30 |
Assay-provider ledger (102)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 8 | June 01, 2026 |
| Interpace Diagnostics | Diagnostic provider | Clinical validationAnalytical validation | 2 | October 16, 2025 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 17 | September 01, 2025 +1 undated |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 2 | September 01, 2025 |
| Caris Life Sciences | Diagnostic provider | Clinical validationAnalytical validation | 1 | August 13, 2025 |
Showing 5 of 102 assay-provider companies.
Actionable biomarkers (17)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NRAS oncogenic mutation | Mek Inhibitors | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| NRAS oncogenic mutation | Mek Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| NRAS (12,13,59,61,117,146) | PANITUMUMAB | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
| NRAS oncogenic mutation | Mek Inhibitor +/- Pi3k Pathway Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| NRAS (12,13,59,61,117,146) | CETUXIMAB | responsive | colorectal adenocarcinoma | Cancer Genome Interpreter |
Showing 5 of 17 actionable-biomarker assertions.
Trial mentions (382)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04050345 | Trial biospecimen (AACT) |
| NCT05365412 | Trial biospecimen (AACT) |
| NCT02823210 | Trial biospecimen (AACT) |
| NCT06750094 | Trial eligibility (AACT) |
| NCT03981614 | Trial eligibility (AACT) |
Showing 5 of 382 trial mentions.
Target-disease associations (591)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Absent tibia - polydactyly | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acheiropodia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acromesomelic dysplasia, Grebe type | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acromesomelic dysplasia, Hunter-Thomson type | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 591 associations.
Vendor sourcing (1,185)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The missense variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reporte... | View ClinVar record SCV002012276.1 |
| ADIR, a Servier Group company | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically or cytologically confirmed adenocarcinoma of metastatic colorectal cancer (mCRC), not amenable to surgical intervention due to either med... | View trial NCT05223673 |
| ADIR, a Servier Group company | Trial collaborator | Primary endpoint in a Phase 3 trialTrial endpoint | Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part) | View trial NCT05223673 |
| ADIR, a Servier Group company | Trial collaborator | Mentioned in trial textTrial free-text mention | NRAS | View trial NCT05223673 |
| AIO Studien gGmbH | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patients with wild-type RAS (KRAS and NRAS) status of metastatic colorectal cancer treatment with panitumumab according to label * RAS wild-type te... | View trial NCT01668498 |
Showing 5 of 1,185 sourcing records.
Trial-cited literature (1,033)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial. | NPJ precision oncology | 2026 | 1 |
| Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study. | Oncology letters | 2026 | 1 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
Showing 5 of 1,033 papers.
Protein variant mentions (48)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A59T | 4 | 2015 to 2022 | PMID 35101943, PMID 34215841, PMID 30981987 |
| p.C1022T | 1 | 2009 | PMID 19718025 |
| p.C1285T | 1 | 2009 | PMID 19718025 |
| p.C1630T | 1 | 2009 | PMID 19718025 |
| p.C2098T | 1 | 2009 | PMID 19718025 |
Showing 5 of 48 variants.
Literature-extracted relations (155)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| CETUXIMAB | Chemical | negative_correlate |
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. | 2022 |
| PANITUMUMAB | Chemical | negative_correlate |
Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. | 2022 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. | 2021 |
| Dacarbazine | Chemical | negative_correlate |
Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. | 2020 |
| PANITUMUMAB | Chemical | associate |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. | 2019 |
Showing 5 of 155 relation assertions.
Organizations publishing (771)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 88 | 2009 to 2025 |
| The University of Texas System | Academic | 84 | 2010 to 2026 |
| Dana-Farber Cancer Institute | Other | 54 | 2011 to 2024 |
| Government of the United States of America | Government | 54 | 2009 to 2024 |
| Mass General Brigham | Hospital | 35 | 2012 to 2024 |
Showing 5 of 771 organizations.
Where NRAS appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
459 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and human sample screening reference.